For Dr Maryam Noparast, health research is both a challenge and a thrill. As part of the global research team at Medlior, Maryam is focused on bringing credible evidence to provide tools for sound decision-making and support the needs of patients.
Dr. Noparast’s extensive background combines research methodology, design and implementation of epidemiological and clinical studies, quantitative statistical data analysis and modeling. Maryam has spent the past 20 years working in a variety of roles and therapeutic areas spanning trauma, surgery, gastrointestinal diseases, urology and oncology. More recently, she contributes her expertise as an independent research consultant with outcomes and research groups, including Medlior, to provide support in scientific evidence generation and medical writing.
With a Medical Degree in hand, Dr Noparast’s passion for medical research grew while working as a trauma and surgery research associate. However, a personal account of loss to cancer motivated Maryam to advance her graduate studies and focus on breast cancer epidemiology, screening and treatment adherence in the developing world. She subsequently focused on interdisciplinary oncology, zeroing in on treatment outcome disparity among ethnic groups in Canada with hematological malignancies.
Maryam shares a deep passion for precision medicine in oncology, histology agnostic targeted therapy in cancer treatment and newer clinical trial designs. She is fascinated by new advancements; the speed, impact and abundance of data being generated in the field of oncology which, according to her, is underutilized in health research.
Maryam likens medical research to an exercise of constant dedication, with the flexibility to change one’s perspective on their current understanding and their clinical practice. She states: “I like both the challenges research presents and the thrill of trying to put the “puzzle pieces” together. In addition, knowing you are contributing novel knowledge that may potentially improve the lives of millions of people is immeasurable”.
Among the global trends Dr. Noparast follows closely are: the evolving models of healthcare and health care solutions, the potential role of artificial intelligence, and the emerging use of big data over the gold standard of data derived from randomised controlled trials (RCTs). These big data, or Real-World Evidence (RWE), provide insight into real-world settings and are more inclusive of a larger variety of patients. This approach allows researchers to translate their findings to more broad audiences than what has traditionally been possible with RCT data. However, Maryam notes, the use of RWE for research needs to be further established in order to ensure quality outcomes and that insights are translated appropriately.